Toshiba nets FDA clearance for two new CT applications
Toshiba America Medical Systems has received FDA clearance for two new CT clinical applications, SURECardio Prospective and Variable Helical Pitch (vHP), which are available with the Toshiba Aquilion 32- and 64-slice CT systems.
The Tustin, Calif.-based Toshiba said its SURECardio Prospective helps reduce patient dose by up to 80 percent during coronary CT angiography exams by using a helical acquisition technique to provide one continuous image instead of multiple images produced by the current step-and-shoot techniques. SURECardio Prospective detects and adjusts to patients with arrthymia, as well as automating scan parameters and reconstruction based on the patient's heart rate, the company said.
The company also said its vHP enables physicians to complete an exam of more than one anatomical region consecutively—without stopping to alter the helical pitch of the exam.
The Tustin, Calif.-based Toshiba said its SURECardio Prospective helps reduce patient dose by up to 80 percent during coronary CT angiography exams by using a helical acquisition technique to provide one continuous image instead of multiple images produced by the current step-and-shoot techniques. SURECardio Prospective detects and adjusts to patients with arrthymia, as well as automating scan parameters and reconstruction based on the patient's heart rate, the company said.
The company also said its vHP enables physicians to complete an exam of more than one anatomical region consecutively—without stopping to alter the helical pitch of the exam.